In a blog post by Daniel Azoulai, Qdrant highlighted how Sapu, an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers, uses Qdrant Cloud infrastructure to power an AI research platform capable of indexing and querying all 28 million PubMed abstracts in a single searchable collection, helping accelerate biomedical discovery workflows.

According to the post, Sapu’s AI platform evolved from an early prototype into a production-scale system supporting scientific literature review, standard operating procedure retrieval and AI-assisted research authorship. The company said the platform has already contributed to seven peer-reviewed research papers while being used broadly across its research operations.

The blog also noted that Sapu is expanding the platform’s capabilities through a robotics partnership with Techforce and evaluating edge deployments for secure, air-gapped laboratory environments. Qdrant’s hybrid vector and metadata retrieval architecture is central to enabling the scale, speed and flexibility required for those next-stage applications.

About Qdrant

Qdrant is a developer-focused provider of vector search technology built to power AI applications at scale. Founded after co-founders André Zayarni and Andrey Vasnetsov identified a gap in existing vector similarity search tools, the company developed a production-ready vector search engine designed to deliver the scalability, performance and feature set needed for real-world AI and machine learning deployments.

What began as an open-source GitHub project has grown into an enterprise-grade platform supporting startups and large-scale organizations alike. Qdrant offers both open-source and managed cloud vector search solutions, giving developers precise control over indexing, search and retrieval of high-dimensional data.

Built in Rust, Qdrant has surpassed 250 million downloads, earned more than 29,000 GitHub stars and grown to a global team of more than 100 employees across 20-plus countries, focused on advancing scalable infrastructure for next-generation AI applications.

For more information, Click Here

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer

AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com

AINewsWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is AINewsBreaks – Qdrant Powers Sapu AI Platform Indexing 28 Million PubMed Abstracts to Accelerate Cancer Research.